Abstract Accumulating studies have focused on circulating microRNAs, which might be potential biomarkers for different malignancies. The aim of this study was to investigate the serum exosomal microRNAs novel smouldering myeloma (SMM) or even multiple (MM). levels and were measured in healthy individuals patients with SMM (n = 20) MM 20). Serum extracted from serum, expression selected quantified by real‐time polymerase chain reaction (PCR). exosome‐derived miR‐20a‐5p, miR‐103a‐3p, miR‐4505...

Circularly permuted TRAIL (CPT), a recombinant mutant of human Apo2L/TRAIL, is novel antitumor candidate for multiple myeloma (MM) and other hematologic malignancies. In this phase II study, the safety efficacy CPT plus thalidomide was investigated in thalidomide-resistant MM patients. A total 43 patients were recruited into three cohorts based on dosage sequence: 5 mg/kg (n = 11), 8 17), 10 15). administered via intravenous infusion days 1-5, given orally at 100 mg once daily each 21-day...

This study evaluated the potential relationship between exosomal miRNAs and clinical symptoms in patients with multiple myeloma (MM). Forty-eight newly diagnosed sixteen normal donors were enrolled study. The results showed that relative expression levels of let-7c-5p, let-7d-5p, miR-140-3p, miR-185-5p, miR-425-5p exosomes MM significantly lower than those healthy controls. Furthermore, there significant differences characteristics myeloma, such as kidney damage, while same miRNA serum are...

The identification of specific cytogenetic abnormalities by interphase fluorescence in situ hybridization (i-FISH) has become a routine procedure for prognostic stratification multiple myeloma (MM) patients. In this study, the significance detected (iFISH) 229 newly diagnosed patients was retrospectively analyzed. Results showed that del (17p), t(4;14), and 1q21 gain were adverse predictors progression-free survival (PFS). Patients who carried these more likely to have biological parameters...

Genetic abnormalities in patients with multiple myeloma (MM) are important risk factors terms of prognosis. In the present study, prognostic value several common MM genetic was investigated. Interphase fluorescence situ hybridization (iFISH) used to detect abnormalities, including 1q21 gain, t(4;14), t(11;14), t(14;16) and 17p13 deletion 131 patients. A total 46.6% were detected one or more using iFISH analysis. The 42.5, 6.9, 17.5, 0.8 10.7% patients, respectively. Patients t(4;14) commonly...

We retrospectively analyzed immunosuppression status in 287 newly diagnosed multiple myeloma (MM) patients and assessed the prognostic value of immunoparesis on survival. Deep was defined that one uninvolved immunoglobulins below 50% lower limit normal ranges, partial at least two suppressed immunoglobulins. found with deep had a significantly shorter median overall survival (OS) progression-free (PFS). Moreover, poor factor for OS PFS univariate multivariable analyses. To reduce bias...

Myelolipoma is a rare, benign neoplasm composed of mature adipocytes and hematopoietic tissue, mainly occurring in the adrenal glands. The majority extra-adrenal myelolipomas have been identified presacral region primary mediastinal myelolipoma very rare. Computed tomography (CT) magnetic resonance imaging (MRI) are effective methods to detect myelolipoma, while fine-needle aspiration (FNA) combined pathology able definitively rule out malignancy. There no standard method treatment for...

The mechanism of the anti-myeloma effect immunomodulatory drug lenalidomide relies upon binding or an analogue to cereblon (CRBN) ubiquitin ligase, which inhibits it and results in degradation Ikaros-family zinc finger proteins 1 3 (IKZF1 IKZF3). To determine whether traditional Chinese medicine arsenic trioxide, could potentiate sensitivity multiple myeloma (MM) cells identify by this happens, present study investigated how trioxide affected CRBN on MM cell lines examined combination...

Recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand (rmhTRAIL) has become a potential therapeutic drug for multiple myeloma (MM). However, the exact targets and resistance mechanisms of rmhTRAIL on MM cells remain to be elucidated. The present study aimed investigate target resistance‑related proteins cell lines. A TRAIL‑sensitive line, RPMI 8226, TRAIL‑resistance one, U266, were chosen differentially expressed between two lines analyzed prior subsequent...

Objective:The management experience for plasma cell leukemia (PCL) is still limited by PCL's rare incidence and aggressive course.The goal of this study was to further identify the efficacy bortezomibcontaining regimens PCL in Chinese patients. Materials Methods:In study, 56 consecutive patients [14 primary (pPCL) 42 secondary (sPCL) cases] were retrospectively enrolled 42/56 received bortezomibbased (BBRs), including 10/14 pPCL 32/42 sPCL patients.The patients' survival data, clinical...

To evaluate the prognostic value of t(4; 14) translocation for newly diagnosed multiple myeloma (MM) patients in novel agent era.We retrospectively analyzed 606 MM treated with agents. The propensity score matching technique was used to reduce bias between groups.Among patients, observed 108 (17.8%) among which 79 (73.1%) were accompanied by 1q21 gain and/or del 17p. Median overall survival (OS) (56.2 vs. 87.3 months) and progression-free (PFS) (25.7 37.6 significantly shorter t(4;14)...

To evaluate the prognostic role of prothrombin time (PT) and activated partial thromboplastin (APTT) for newly diagnosed multiple myeloma (MM).We retrospectively analyzed 354 patients with MM who received primary treatment in our center. The propensity score matching technique was used to reduce bias between groups.Among patients, lengthened PT or APTT observed 154 (43.5%) 200 (56.5%) had normal APTT. Patients significantly shorter median overall survival (OS) (37.5 vs. 73.8 months, p <...

We retrospectively studied the impact of cytogenetic abnormalities in 328 consecutive newly diagnosed multiple myeloma (MM) patients. High-risk (HRCAs) included del (17p), amp/gain (1q21), t(4;14), and t(14;16). defined a standard-risk group by absence HRCA, an intermediate-risk with one high-risk (HiR) at least two HRCAs. The HiR constituted 14.3% patients was associated median overall survival (OS) 28.6 months progression-free (PFS) 14.0 months. Moreover, predicted poor outcomes for OS PFS...

Abstract Background Pulmonary hypertension (PH) is a common but rarely recognized comorbidity of multiple myeloma (MM) patients, while its prognostic significance for MM has been reported. Methods We retrospectively analyzed the clinical characteristics and value baseline echocardiography‐defined PH in 426 newly diagnosed (NDMM) patients. Results Echocardiograph‐defined was found 12.7% (54/426) NDMM associated with older age, anemia, renal insufficiency, as well severe diastolic dysfunction...

Translocation (11;14) is one of the most frequent recurrent cytogenetic abnormalities in multiple myeloma (MM), while its clinical prognostic value remains controversial. CD20 expression uncommon MM strongly associated with t(11;14). This study aimed to investigate whether could provide further patients harboring t(11;14).CD20 detected by flow cytometry was retrospectively analyzed 211 newly diagnosed The characteristics and outcomes were between positive negative patients.CD20 found 34.6%...

Multiple myeloma (MM) is the second most common hematological malignancy in China. However, there are only a small number of large cohort studies demonstrating clinical features newly diagnosed MM. In present study, 264 MM patients from Beijing Chaoyang Hospital were retrospectively analyzed. The median patient age was 59 years (range, 28‑84) and monoclonal protein (42%) IgG subtype. Of 49 detected by FISH, 10.2, 2.0 12.2% demonstrated del(17p), t(14;16) t(4;14), respectively. total, 228...

To investigate the incidence and risk factors for osteonecrosis of femoral head (ONFH) in multiple myeloma (MM) patients undergoing dexamethasone-based regimens (DBRs).A retrospective study was conducted MM administered DBRs between December 2012 April 2015. Demographic, clinical, laboratory data were extracted to compare two groups. Incidence ONFH calculated identified by both univariate multivariate analysis.The group comprised 105 DBRs. Seven with after classified as group, other 98...

In this study, the case of a 60-year-old female patient who presented with subcutaneous mass in lower right limb is described. The was confirmed as plasmacytoma. diagnosed multiple myeloma (MM) λ type stage III international system (ISS) and received three cycles therapeutic PDT regimen (bortezomib, dexamethasone thalidomide) complete remission achieved. Following further two regimen, proceeded to high-dose cyclophosphamide combined granulocyte-colony stimulating factor (G-CSF) for stem cell...

To analyze the effects of bortezomib on prognosis newly diagnosed multiple myeloma patients with renal impairment, we assessed outcomes 134 impairment (serum creatinine ≥178 μmol/l) who were treated at Beijing Chaoyang Hospital. The divided into two groups: (n = 83) and nonbortezomib 51). overall response rate group was higher than that group. There no significant difference in time to restore function, but complete ratio significantly 2-year survival (OS) greater group, as 3-year OS rate....

Objective: To investigate the clinical characteristics and risk factors of ultra-high-risk (UHR) patients with newly diagnosed multiple myeloma (MM). Methods: We screened UHR a survival less than 24 months we selected concurrent more as control group. retrospectively analyzed MM related factors. Results: In total 477 patients, which included 121 (25.4%) 356 (74.6%) patients. Median overall (OS) progression-free (PFS) was 10.5 (7.5–13.5 months) 6.3 (5.4–7.2 months), respectively. Univariate...

Tumor necrosis factor related apoptosis inducing ligand (TRAIL) is a promising anti‑myeloma drug prototype. The aim of the present study was to investigate synergistic effects cyclopamine and circularly permuted TRAIL (CPT) on proliferation multiple myeloma cells. results showed that inhibitory human RPMI‑8226 SKO‑007 cells were weak. sensitive CPT; however, not effectively inhibited by CPT. thus considered resistant CPT used for subsequent experiments. Treatment with combination...

The objective of the present study was to conduct a retrospective analysis clinical characteristics group patients with multiple myeloma (MM) who had two different immunoglobulin λ light chains as determined by immunofixation electrophoresis (IFE). A total 26 MM IFE at diagnosis in hospital from January 2006 June 2012. Data were collected medical records these patients. characteristics, laboratory parameters, responses, risk factors and outcomes this special retrospectively analyzed....

The efficacy and safety evidence of bortezomib in multiple myeloma (MM) patients with hepatitis B is vacant. This study aimed to investigate the MM China.From 2006 2011, 739 newly diagnosed were screened for serum virus (HBV) biomarkers. HBV-infected followed HBV reactivation by monitoring alanine transaminase (ALT) DNA load. pattern relation was evaluated. Seven hundred thirty-nine included this study.The prevalence infected 3.4% (n = 25), which 17 cases treated bortezomib. Bortezomib had...

To verify the predictive value of Second Revision International Staging System (R2-ISS) in newly diagnosed patients with multiple myeloma (MM) who underwent first-line autologous hematopoietic stem cell transplantation (ASCT) a new drug era China.